Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hartmann2016 - Blood coagulation model for simulating anticoagulants

ABSTRACT: Mathematical model of blood coagulation. Reused Wajima2009 model with modifications to reactions 27 (formation of Va:Xa complex), 32 (Xa inhibition by TFPI) and 45 (Xa inhibition by TFPI-Heparin complex) as described in publication equations 2,3 and 4. Publication lists parameter sets to simulate Rivaroxaban, VKA and Enoxaparin (supplementary files).

SUBMITTER: Matthew Roberts

PROVIDER: MODEL1807180004 | BioModels | 2018-07-18

REPOSITORIES: BioModels

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MODEL1807180004?filename=Hartmann2016.cps	Other
	MODEL1807180004?filename=Hartmann2016.xml	Xml

Items per page:

1 - 2 of 2

Publications

Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network.

Hartmann S S Biliouris K K Lesko L J LJ Nowak-Göttl U U Trame M N MN

CPT: pharmacometrics & systems pharmacology 20160920 10

Warfarin is the anticoagulant of choice for venous thromboembolism (VTE) treatment, although its suppression of the endogenous clot-dissolution complex APC:PS may ultimately lead to longer time-to-clot dissolution profiles, resulting in increased risk of re-thrombosis. This detrimental effect might not occur during VTE treatment using other anticoagulants, such as rivaroxaban or enoxaparin, given their different mechanisms of action within the coagulation network. A quantitative systems pharmaco ...[more]

PMID: 27647667

Similar Datasets

Zhou2015 - Blood coagulation model predicting effects of factor Xa inhibitors

Project description:Blood coagulation model investigating effects of Xa-inhibitors (Rivaroxaban and Apixaban). Model is an extension of Pohl1994 and reduced from Wajima2009. Encoding the model from the supplementary files results in 43 species, 82 reactions and 111 parameters. Including the drug (Xa-inhibitor) and drug-Xa complexes results in 46 species, 84 reactions and 115 parameters (+1 dummy variable to change inhibitory kinetic parameters depending on which drug is simulated). The publication lists there being 45 species, 84 reactions and 116 parameters. Publication figure 2 has 45 species present however the complex VIIa:Xa (reaction 51 involving Xa and VIIa) is not shown. This figure also has numerous small errors such as listing IXa:ATIII complex twice (instead of one being XIa:ATIII), not showing XIa:ATIII, typo ('Va' -> Va), typo (IXa + VIIIa -> IXA:'VIIa'). Rate laws for Xa-drug interactions were assumed to be mass action.

2018-06-07 | MODEL1806070001 | BioModels

Willems1991 - Simulating thrombin generation

Project description:Mathematical model of blood coagulation to simulate factor IIa, Va and Xa concentration profiles. Publication also illustrates the effect of hirudin on factor IIa, Va and Xa generation.

2018-07-24 | MODEL1807240002 | BioModels

Nagashima2002 - Simulating blood coagulation inhibitory effects

Project description:Mathematical model of blood coagulation and the effects of inhibitors of Xa, Va:Xa and IIa.

2024-09-02 | BIOMD0000000747 | BioModels

Panteleev2002_TFPImechanism_schmema1

Project description:Mikhail A. Panteleev, Veronica I. Zarnitsina & Fazoil I. Ataullakhanov. Tissue factor pathway inhibitor: a possible mechanism of action. European Journal of Biochemistry 269, 8 (2002). We have analyzed several mathematical models that describe inhibition of the factor VIIa-tissue factor complex (VIIa-TF) by tissue factor pathway inhibitor (TFPI). At the core of these models is a common mechanism of TFPI action suggesting that only the Xa-TFPI complex is the inhibitor of the extrinsic tenase activity. However, the model based on this hypothesis could not explain well all the available experimental data. Here, we show that a good quantitative description of all experimental data could be achieved in a model that contains two more assumptions. The first assumption is based on the hypothesis originally proposed by Baugh et al. [Baugh, R.J., Broze, G.J. Jr & Krishnaswamy, S. (1998) J. Biol. Chem. 273, 4378-4386], which suggests that TFPI could inhibit the enzyme-product complex Xa-VIIa-TF. The second assumption proposes an interaction between the X-VIIa-TF complex and the factor Xa-TFPI complex. Experiments to test these hypotheses are suggested.

2024-09-02 | BIOMD0000000361 | BioModels

Panteleev2002_TFPImechanism_schmema2

2024-09-02 | BIOMD0000000360 | BioModels

Baugh1998 - Regulation of coagulation factor Xa by TFPI

Project description:Basic mathematical model of the formation of coagulation factor Xa involving TF:VIIa and its inhibition by TFPI.

2018-07-18 | MODEL1807180001 | BioModels

Bravo2012 - Modelling blood coagulation factor Va inactivation by APC

Project description:Mathematical model of blood coagulation factor Va and Va fragment inactivation by APC, reactions with Xa and prothrombinase-prothrombin complex formation.

2024-09-02 | BIOMD0000000739 | BioModels

Orfeo2010 - Simulating the effects of fondaparinux and Rivaroxaban on thrombin generation

Project description:Reused mathematical model (Hockin et al., 2002) of blood coagulation simulating the effects of coagulation factor inhibitors, fondaparinux (synthetic heparin) and Rivaroxaban. Fondaparinux (Fpx) simulated to reversibly bind with ATIII before irreversibly binding to Xa, IXa, mIIa, TF:VIIa, Xa:Va and IIa. Rivaroxaban simulated to bind reversibly to Xa and Xa:Va.

2018-07-24 | MODEL1807240001 | BioModels

Xu2005 - Blood Coagulation Model of Activated Factors of Extrinsic Pathway and TFPI

Project description:System of ODEs to describe the behaviour of the activated factors of the extrinsic pathway of blood coagulation with the addition of the TFPI-Xa complex. Mass-action kinetics used with the only exception of factor IIa production (Michaelis-Menten rate law).

2018-06-13 | MODEL1806130002 | BioModels

[E-MTAB-345] ChIP-Seq of human MCF-7 cells with anti-ERalpha following estrogen treatment

Project description:We performed chromatin immunoprecipitation (ChIP) with overnight with antibodies against the C-terminus (HC-20, from Santa Cruz Biotechnology, Europe) or the N-terminus (anti-Estrogen Receptor 18-32, from SigmaAldrich, Italy) of human ER-alpha with or without estrogen treatment for 45 minutes on TAP-ER-beta cells, and the immunoprecipitated DNA was sequenced with the Illumina/Solexa Genome Analyzer. (Note: Raw data files not provided by submitter) Publication Title: Global analysis of ERbeta binding to human breast cancer cell genome Publication Author List: Grober OMV, Mutarelli M, Paris O, Giurato G, De Filippo MR, Cicatiello L, Ravo M, Ferraro L, Nassa G, Tarallo R, Papa MF, Benes V, Alessandro Weisz. ArrayExpress Release Date: 2010-10-05 Person Roles: submitter Person Last Name: Weisz Person First Name: Alessandro Person Mid Initials: Person Email: alessandro.weisz@unina2.it Person Phone: Person Address: Person Affiliation: Second University of Naples

2011-02-05 | GSE25769 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data